Table 2 Mendelian randomization analyses of the causal effects between T cells, plasma metabolites and malignant brain tumors
From: Role of T cell metabolism in brain tumor development: a genetic and metabolic approach
T cell | Metabolite | Outcome | Mediated Effect | Mediated proportion |
|---|---|---|---|---|
Naïve CD8 + T cell Absolute Count | Octadecanedioylcarnitine (C18-DC) levels | malignant brain tumors | -0.00370 | 10.8% |
| Â | Eicosanedioate (C20-DC) levels | malignant brain tumors | -0.00317 | 9.2% |
Naïve CD8 + T cell %T cell | Octadecanedioylcarnitine (C18-DC) levels | malignant brain tumors | -0.00336 | 11.2% |
| Â | Eicosanedioate (C20-DC) levels | malignant brain tumors | -0.00271 | 9.0% |
CD28 − CD8 + T cell % CD8 + T cell | 5-dodecenoate (12:1n7) levels | malignant brain tumors | -0.02637 | 13.2% |
| Â | Arachidonate (20:4n6) levels | malignant brain tumors | -0.01340 | 6.7% |
| Â | Glycerol to glycerol 3-phosphate ratio | malignant brain tumors | -0.01672 | 8.4% |
HLA_DR_on_HLA_DR+_CD8+_T_cell | Glyco-beta-muricholate levels | malignant brain tumors | -0.00867 | 4.0% |
Secreting CD4 regulatory T cell Absolute Count | 17alpha-hydroxypregnanolone glucuronide levels | malignant brain tumors | -0.00344 | 5.9% |
CD127- CD8 + T cell Absolute Count | Tyrosine levels | malignant brain tumors | -0.0182 | 8.8% |
| Â | Glyco-beta-muricholate levels | malignant brain tumors | -0.00948 | 4.6% |